Bulk Pharmaceutical API Sources for pyrimethamine; sulfadoxine

Bulk Pharmaceutical API Sources for pyrimethamine; sulfadoxine

Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem		B1208122
THE BioTek		bt-1546543
J&H Chemical Co.,ltd		JH278292
RR Scientific		R201500
EvitaChem		evt-1546543

Bulk API Sources: Pyrimethamine & Sulfadoxine

Last updated: February 19, 2026

This report identifies key global manufacturers of bulk active pharmaceutical ingredients (APIs) for pyrimethamine and sulfadoxine. It details their manufacturing capacities, regulatory compliance, and supply chain considerations, providing data for strategic sourcing and market assessment.

What are the primary applications of pyrimethamine and sulfadoxine?

Pyrimethamine is an antiparasitic medication used to treat and prevent malaria, toxoplasmosis, and is sometimes used in combination with other drugs for Pneumocystis pneumonia. Sulfadoxine is a sulfonamide antibiotic primarily used in combination with pyrimethamine as a long-acting treatment for malaria, specifically in intermittent preventive treatment during pregnancy (IPTp) and as a treatment for uncomplicated malaria.

Who are the leading global manufacturers of Pyrimethamine API?

Several manufacturers globally produce pyrimethamine API. Key players include:

• Novartis AG (Switzerland): A major pharmaceutical company with a long history in antimalarial drug production. While Novartis' primary focus is on finished dosage forms and drug development, they maintain strong ties to API manufacturing, either in-house or through contracted partners. Their historical involvement in antimalarials suggests potential for significant pyrimethamine API sourcing capabilities.
• API manufacturers in India: India is a significant hub for API production, with numerous companies capable of synthesizing pyrimethamine. Notable potential suppliers include:
  • Sun Pharmaceutical Industries Ltd.: One of India's largest pharmaceutical companies, with extensive API manufacturing facilities and a broad product portfolio.
  • Dr. Reddy's Laboratories: A global pharmaceutical company with strong API manufacturing capabilities.
  • Laurus Labs: Known for its expertise in complex API synthesis.
  • Divi's Laboratories: A prominent API manufacturer with a large-scale production capacity.
• API manufacturers in China: China also hosts a substantial number of API manufacturers. Potential suppliers include:
  • Hengdian Group: A diversified conglomerate with a significant pharmaceutical division, often involved in API production.
  • Zhejiang NHU Co., Ltd.: A large chemical and pharmaceutical group with substantial API manufacturing operations.
  • Jiangsu HEC Pharmaceutical Co., Ltd.: Involved in the production of various pharmaceutical intermediates and APIs.
• Other Manufacturers: Companies in other regions may also produce pyrimethamine API, though often in smaller volumes or for regional markets.

What are the primary global manufacturers of Sulfadoxine API?

Similar to pyrimethamine, sulfadoxine API production is concentrated in India and China, with some European players also in the market.

• API manufacturers in India: Indian manufacturers are significant suppliers of sulfadoxine API.
  • Sun Pharmaceutical Industries Ltd.: As with pyrimethamine, Sun Pharma's broad API capabilities likely include sulfadoxine.
  • Dr. Reddy's Laboratories: A strong contender for sulfadoxine API supply.
  • Divi's Laboratories: A well-established manufacturer with the capacity for large-scale API production.
  • Aurobindo Pharma: A major Indian pharmaceutical company with significant API manufacturing facilities.
• API manufacturers in China: Chinese manufacturers play a crucial role in the global supply chain.
  • Zhejiang NHU Co., Ltd.: A likely producer given their extensive chemical and pharmaceutical operations.
  • Hengdian Group: May also be involved in sulfadoxine API production.
  • Fujian Tonteng Chemical Industry Co., Ltd.: Another Chinese chemical and pharmaceutical producer with potential for API supply.
• European Manufacturers: While less dominant than Asian producers for high-volume generics, some European companies may produce sulfadoxine API, potentially for specialized markets or as part of integrated supply chains.

What are the regulatory considerations for these APIs?

Compliance with stringent regulatory standards is critical for sourcing pyrimethamine and sulfadoxine APIs, especially for pharmaceutical applications. Key regulatory aspects include:

• Good Manufacturing Practices (GMP): Manufacturers must adhere to cGMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). This ensures product quality, safety, and consistency.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities. These confidential documents contain detailed information about the manufacturing process, facilities, quality control, and stability of the API. Pharmaceutical companies reference these DMFs in their drug product applications.
• Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEPs): A CEP is issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and demonstrates that the quality of a substance is suitably controlled by the relevant monograph of the European Pharmacopoeia. This simplifies the regulatory process for drug product manufacturers in Europe and other countries that recognize CEPs.
• Pharmacopoeial Standards: APIs must meet the purity and quality specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines provide harmonized standards for pharmaceutical development and registration, including those related to API manufacturing and quality.
• Supply Chain Audits: Pharmaceutical companies conduct rigorous audits of their API suppliers to verify compliance with GMP, quality systems, and ethical manufacturing practices.

What are the typical production capacities and scale of these APIs?

Production capacities for pyrimethamine and sulfadoxine APIs vary significantly among manufacturers.

• Large-Scale Manufacturers (India & China): Major Indian and Chinese API producers often have capacities ranging from tens to hundreds of metric tons per year for high-demand APIs. For drugs like pyrimethamine and sulfadoxine, which are used in essential medicines, capacities can be scaled to meet global public health needs.
• Specialty Manufacturers: Smaller manufacturers or those focused on specific markets might have capacities in the kilogram to low-tonnage range.
• Batch Production: API manufacturing is typically conducted in batches. The size of these batches can range from several hundred kilograms to several thousand kilograms, depending on the equipment and demand.
• Factors Influencing Capacity: Actual production output is influenced by:
  • Demand: Global malaria prevalence and treatment protocols directly impact demand.
  • Regulatory Approvals: Manufacturers must have the necessary regulatory approvals to supply specific markets.
  • Raw Material Availability: The supply and cost of upstream raw materials are crucial.
  • Manufacturing Efficiency: Process optimization and yield improvements affect overall output.

What are the key supply chain considerations for sourcing these APIs?

Sourcing pyrimethamine and sulfadoxine APIs involves several critical considerations:

• Geopolitical Stability: Reliance on a single geographic region for API supply can pose risks. Diversifying suppliers across different countries mitigates risks associated with political instability, trade disputes, or natural disasters.
• Raw Material Sourcing: The availability and cost of precursor chemicals are vital. Understanding the supply chain for these raw materials, often originating from China and India, is essential.
• Lead Times: API production and delivery can involve significant lead times, often ranging from 12 to 24 weeks. This necessitates proactive planning and inventory management.
• Quality Control and Assurance: Robust quality control systems, including batch testing, impurity profiling, and stability studies, are paramount. This involves ensuring that APIs meet stringent pharmacopoeial standards and regulatory requirements.
• Logistics and Transportation: Secure and compliant transportation methods are required to maintain API integrity and prevent contamination. This includes temperature-controlled shipping where necessary.
• Supplier Reliability and Audits: Establishing relationships with reliable suppliers who consistently meet quality and delivery expectations is crucial. Regular audits of manufacturing sites are standard practice.
• Intellectual Property (IP) and Patent Landscape: While pyrimethamine and sulfadoxine are off-patent compounds, understanding any potential patent issues related to novel manufacturing processes or polymorphs is important for long-term sourcing strategies.
• Cost Competitiveness: Sourcing decisions often balance quality and reliability with cost. Manufacturers in India and China generally offer competitive pricing due to economies of scale and lower manufacturing overheads.

What is the market outlook for Pyrimethamine and Sulfadoxine APIs?

The market for pyrimethamine and sulfadoxine APIs is influenced by global health initiatives, disease prevalence, and public health policies.

• Malaria Control Programs: The continued focus on malaria eradication and control by organizations like the WHO and national governments drives demand for antimalarial APIs.
• Intermittent Preventive Treatment in Pregnancy (IPTp): Sulfadoxine-pyrimethamine (SP) is a cornerstone of IPTp strategies in many malaria-endemic regions. The effectiveness and widespread adoption of IPTp directly correlate with demand for SP APIs.
• Toxoplasmosis Treatment: Pyrimethamine's use in treating toxoplasmosis, particularly in immunocompromised individuals, contributes to its market demand, albeit at a smaller scale than antimalarial applications.
• Resistance Patterns: The emergence of drug resistance can influence the demand for specific antimalarial combinations. However, sulfadoxine-pyrimethamine remains a recommended treatment in many areas where resistance to other antimalarials is high.
• Generic Competition: As both APIs are off-patent, the market is characterized by significant generic competition, leading to price pressures and a focus on cost-effective manufacturing.
• Emerging Markets: The highest demand originates from sub-Saharan Africa, Southeast Asia, and parts of South America, where malaria is endemic.

Key Takeaways

• Global production of pyrimethamine and sulfadoxine APIs is primarily concentrated in India and China, with companies like Sun Pharma, Dr. Reddy's Laboratories, Divi's Laboratories, and Zhejiang NHU Co., Ltd. being significant players.
• Regulatory compliance, including GMP adherence, DMF submission, and meeting pharmacopoeial standards, is paramount for API suppliers serving regulated markets.
• Production capacities for major manufacturers can reach tens to hundreds of metric tons annually, scalable based on global health needs.
• Supply chain management requires careful consideration of geopolitical stability, raw material sourcing, lead times (12-24 weeks), quality assurance, and logistical integrity.
• Market demand is largely driven by global malaria control programs and the use of sulfadoxine-pyrimethamine in IPTp strategies, with ongoing generic competition influencing pricing.

Frequently Asked Questions

1. What are the main differences in the regulatory pathways for APIs from India versus China? While both Indian and Chinese manufacturers must comply with cGMP standards recognized globally (e.g., FDA, EMA), the specific regulatory filings (e.g., Drug Master Files, Certificates of Suitability) and inspection frequencies can differ based on the target market and the regulatory authority of the importing country. The FDA and EMA conduct rigorous inspections of manufacturing sites regardless of origin.

2. How can a pharmaceutical company ensure consistent quality when sourcing APIs from multiple global suppliers? Companies implement comprehensive quality assurance programs including rigorous supplier qualification processes, site audits, raw material testing, in-process controls, and final API batch testing against pre-defined specifications. Establishing strong quality agreements with each supplier is also critical.

3. What impact does the patent status of pyrimethamine and sulfadoxine have on their API sourcing strategy? Since both compounds are off-patent, their API sourcing is primarily driven by manufacturing cost, quality, reliability, and regulatory compliance. The absence of patent barriers allows for a wider pool of manufacturers, increasing competition and potentially lowering prices. However, patenting of novel, more efficient, or environmentally friendly manufacturing processes is possible and could influence sourcing decisions if those processes offer significant advantages.

4. What are the primary risks associated with a concentrated API supply chain in only one or two countries? Concentrated supply chains are vulnerable to geopolitical events, trade policy changes, natural disasters, and localized regulatory crackdowns. Such disruptions can lead to shortages, price volatility, and significant delays in drug availability. Diversification across multiple countries and manufacturers is a key risk mitigation strategy.

5. Are there emerging regional manufacturers of pyrimethamine and sulfadoxine APIs outside of India and China? While India and China dominate high-volume API production due to established infrastructure and cost efficiencies, some manufacturers in other regions, such as parts of Eastern Europe or specific facilities in South America, may produce these APIs for regional markets or specialized pharmaceutical applications. However, these are generally not primary global suppliers for high-volume, cost-sensitive markets.

Citations

[1] World Health Organization. (2023). Malaria. https://www.who.int/news-room/fact-sheets/detail/malaria [2] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). https://www.fda.gov/drugs/drug-master-file-dmf/ [3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). https://www.edqm.eu/en/certificate-suitability-monographs-european-pharmacopoeia-cep [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. https://www.ich.org/page/ich-guidelines [5] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. https://www.uspnf.com/